Mon, Apr 21, 2014, 7:03 AM EDT - U.S. Markets open in 2 hrs 27 mins

Recent

% | $
Quotes you view appear here for quick access.

Teva Pharmaceutical Industries Limited Message Board

  • bluecheese4u bluecheese4u Feb 7, 2013 3:13 PM Flag

    Teva Reports Fourth Quarter and Full Year 2012 Results

    Teva Reports Fourth Quarter and Full Year 2012 Results

    Click here for Webcast
    Fourth Quarter 2012 Net Revenues of $5.2 Billion and Full Year Net Revenues of $20.3 Billion
    Fourth Quarter 2012 Non-GAAP Diluted EPS of $1.32, GAAP Diluted EPS of $0.37; Full Year Non-GAAP Diluted EPS of $5.35, GAAP Diluted EPS of $2.25
    15% Increase in Quarterly Dividend
    Share Repurchases of $0.5 Billion and $1.2 Billion in Fourth Quarter and Full Year 2012, Respectively
    Cash Flow from Operations of $1.6 Billion and $4.6 Billion in Fourth Quarter and Full Year 2012, Respectively

    JERUSALEM--(BUSINESS WIRE)--Feb. 7, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today reported results for the quarter and year ended December 31, 2012.
    “Our efforts over the past year clearly demonstrate Teva's ability and commitment to transform the Company. Based on this, we will enter 2013 with a strong and disciplined business focus," stated Dr. Jeremy Levin, Teva’s President and Chief Executive Officer. "Our generic franchise remains the core of our business. We launched 23 generic products in the U.S. in 2012, and anticipate a similar number of launches in 2013. Our specialty medicines business continues to drive value with strong fundamentals in multiple sclerosis, central nervous system, respiratory, oncology and women’s health. Copaxone® continues to lead the multiple sclerosis market in sales and market share. In March 2013, we plan to submit to the FDA a sNDA for marketing approval of a '3 times a week' dose of Copaxone®. Our new R&D organization is showing great progress. Our New Therapeutic Entities pipeline is advancing as expected. At the same time, we are beginning to add external opportunities through our 'Constellation' business development program. We have launched our 'Reshape' program and are committed to managing our costs while we invest in Teva’s future."
    Dr. Levin added, "I am particularly pleased with the Board's decision to increase Teva's dividend. Together with Teva's new strategy backed by our ongoing share repurchase plan, this decision reflects the Board's and management's optimism and confidence. We believe the course we have set for Teva is the right one and will yield real value for patients, customers and shareholders while ensuring the long-term growth of our company."
    Revenues by Geography for the Fourth Quarter 20121
    Net revenues in the United States in the fourth quarter were $2.6 billion (50% of total revenues), a decrease of 14% compared to the fourth quarter of 2011. Provigil® sales declined substantially due to generic competition that began in the second quarter of 2012, while the other factor affecting the comparison is the unusually high generic revenues during the fourth quarter of 2011 due to extraordinary contributions from our launch of generic Zyprexa® and from our agreement with Ranbaxy relating to its launch of generic Lipitor®. The absence of these contributions in the fourth quarter of 2012 was partially offset by strong revenues from generic launches throughout 2012, as well as an increase in Copaxone® sales
    Net revenues in Europe in the fourth quarter were $1.5 billion (29% of total revenues), an increase of 2% compared to the fourth quarter of 2011, or 5% in local currency terms. Revenues in Europe this quarter benefited from stronger revenues from some of our specialty medicines, primarily Copaxone®, following the take-back of marketing and distribution rights, as well as increased sales from our OTC business. We are continuing to manage our commercial model in Europe in line with our strategy of sustainable and profitable growth.
    Net revenues in the Rest of the World in the fourth quarter totaled $1.1 billion (21% of total revenues), a decrease of 3% compared to the fourth quarter of 2011. In local currency terms, ROW revenues declined by 2%. The slight decline in revenues resulted from the sale of certain businesses of Mepha AG, which closed in the first quarter of 2012, as well as weaker performance in Canada, due primarily to government-imposed price reforms. This decrease was partially offset by growth in Latin America.

    irDOTtevapharmDOTcom/phoenixDOTzhtml?c=73925&p=irol-newsArticle&ID=1782674&highlight=

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
TEVA
50.85+0.94(+1.88%)Apr 17 4:04 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.